MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

What happened

MacroGenics announced positive interim Phase 2 LINNET results for lorigerlimab, a bispecific antibody targeting PD-1 and CTLA-4, in advanced clear cell gynecologic cancer. Data presented at ESMO 2026 showed a 25% response rate and manageable tolerability in this difficult-to-treat cancer subtype.

Confirmed

Global impact / market context

A 25% response rate for a single treatment in a cancer resistant to platinum-based chemotherapy could justify further development spending on lorigerlimab. Positive mid-stage data may also strengthen MacroGenics' negotiating position in partnering discussions, potentially bringing in cash or offsetting research costs.

Analyst inference

Clinical-stage biopharmaceutical investors often treat positive interim trial data as a signal for future capital spending and partnership potential. Because MacroGenics has no approved product in this program, investor positioning around the stock can shift sharply with each data release.

Analyst inference

What to watch

1. MacroGenics said the LINNET data covered 41 patients with advanced gynecologic cancers, including 24 with platinum-resistant ovarian cancer and 17 with clear cell gynecologic cancer. Confirmed
2. Investors should watch whether MacroGenics announces a larger or registrational trial for lorigerlimab, since that step would require added capital spending and could lengthen the path to approval. Proposed
3. Watch for updated duration of response and safety details from LINNET, as longer follow-up could confirm whether the 25% response rate holds and whether side effects remain manageable for patients. Analyst inference

Evidence

• globenewswire.com